Revolution Medicines Achieves FDA Approval for Rasonque, Reaching $47B Valuation
On August 27, 2026, Revolution Medicines (NASDAQ:RVMD) reached an all-time high above $224 following the U.S. Food and Drug Administration's approval of its drug Rasonque for metastatic pancreatic cancer — a first-in-class therapy targeting broad RAS mutations. The milestone was achieved under the agency’s national priority voucher, with clinical trials showing nearly doubled median overall survival compared to chemotherapy. Despite this breakthrough, Revolution Medicines' $47 billion valuation suggests that much of its market optimism has already been priced in. While analysts project significant future sales potential for Rasonque — up to $15.1 billion by 2034 — the current label is limited to second-line or multiagent-ineligible patients, excluding a larger front-line opportunity. The company now faces challenges launching its first commercial product independently in one of oncology’s most difficult markets. With high costs and no existing revenue stream, Revolution Medicines must execute flawlessly while managing expectations from investors who have already priced in success.
